SciGen are to establish a manufacturing facility in China in a
response to the growing demand for the Hepatitis B (HBV) vaccine
and insulin, which has reached epidemic proportions with 2 billion
people having become infected with...
Generex Biotechnology announced its Oral-lyn, the first
non-injectable form of recombinant human insulin available for
commercial distribution anywhere in the world is being launched in
Ecuador to soon become available through physician...
Bentley has accelerated the path to launching its novel intranasal
spray insulin, signing a license agreement with India's Biocon to
develop and market the product in 85 countries throughout Asia,
Africa, and the Middle East.
SemBioSys Genetics has demonstrated bio-equivalence of a
plant-produced insulin, which if realised, could become a viable
alternative to meet the demand for insulin as the incidence of
diabetes increases worldwide.
Generex has escalated manufacturing capabilities to meet expected
demand for the first ever commercially available non-injectable
insulin product, to be launched in Ecuador at the end of the month.
Coremed has introduced its proprietary drug-delivery platform
technology that improves absorption of certain proteins and
macromolecules such as insulin within the gastrointestinal tract.
The first non-injectable insulin treatment in Europe may soon
become available after a panel of experts recommended it for
regulatory approval on Thursday.
Merck Sharp & Dohme (MSD), the UK subsidiary of Merck & Co
of the US, is to partner with the European Foundation for the Study
of Diabetes (EFSD), to further explore a novel area of diabetes
research.
Diabetics moved a step closer to having an alternative to
injections for their insulin therapy yesterday, after a US Food and
Drug Administration (FDA) advisory committee gave its backing to an
inhaled formulation of the drug developed...
Biovitrum and Santhera have announced the signing of an exclusive
license and collaboration agreement, which aims to develop DPP-IV
inhibitors for the treatment of type 2 diabetes and other metabolic
diseases.
Pharmaceutical company, Takeda, has struck a deal with
pharmaceutical services provider, PPD, in which it has acquired the
rights to all dipeptidyl peptidase IV (DPP4) inhibitors - one of a
new generation of agents for diabetes treatment.
European researchers have discovered that treatment with an
antibody preserved the beta cell function, decreasing the insulin
need for at least 18 months in people with recent-onset type 1
diabetes. The discovery represents an important...
An inhaled formulation of insulin developed by MannKind has been
shown to mimic the normal insulin response after a meal and reduce
glucose levels sooner than conventional insulin injections,
reports Phil Taylor.
The latest research included in the proceedings of the annual
scientific meeting of the American Diabetes Association (ADA) means
that diabetic treatments and other therapies for the disease
feature strongly in DrugResearcher's...
The founder, chairman and chief executive of French drug delivery
company Flamel Technologies has been lambasted by disgruntled
shareholders who want to bring in a new management team, writes
Phil Taylor.
Living Cell Technologies (LCT) are set to put a major dent in the
market for diabetic treatments after they announced the retrieval
of live, insulin-producing cells, from a patient, in a transplant
that did not require the use of...
A new understanding of specialised gut hormones may lead to
advances in the treatment and management of type 2 diabetes,
offering patients a viable option in controlling fluctuating blood
glucose levels that is characteristic of the...
Canadian company Generex Biotechnology has stolen a march on its
larger rivals in the pharmaceutical industry by winning regulatory
approval for the world's first non-injectable insulin formulation,
reports Phil Taylor.
Innodia are to initiate a phase I trial of its lead drug candidate
for the treatment of type 2 diabetes with a view to bringing this
novel drug to market and the 170 million people affected by the
disease, a number that is expected...
Canadian biopharmaceutical company, Theratechnologies, has
announced positive results for its latest drug candidate for the
treatment of type II diabetes. The GLP-1 analogue takes its
position in the market for this rapidly evolving...
Drug therapies for sufferers of diabetes may become a thing of the
past as UK doctors performed a groundbreaking cell transplant
technique on a patient making him the first person to be "cured" of
the illness.
US pharmaceutical giant Pfizer and French drugmaker Sanofi-Aventis
have filed with the US Food and Drug Administration seeking
marketing approval for Exubera, an inhaled human insulin powder,
for the treatment of diabetes.
US scientists have demonstrated that by knocking out two key
signals in liver cells causes diabetes. These findings pave the way
for drug strategies to boost these two different signals and treat
the different metabolic components...
Arena Pharmaceuticals has entered into collaboration with
Ortho-McNeil Pharmaceutical to develop a new class of oral drugs
for the treatment of type 2 diabetes. Arena can expect to net $300
million (€224 million) excluding milestone...
Bentley Pharmaceuticals has successfully delivered insulin to type
1 diabetics using its novel intranasal formulation, throwing its
hat into the ring of companies seeking to replace insulin
injections with more patient-friendly options.
Danish pharmaceutical company Novo Nordisk has inked a deal with a
US medical device manufacturer that will extend the use of insulin
cartridges from autoinjectors to external insulin pumps.
US drug delivery company Emisphere Technologies reported promising
results last week with an oral formulation of insulin that could do
away with the need for injections in people with diabetes.
Animas has entered into a license and development agreement with
Debiotech, which aims to develop the next generation of insulin
pumps and micro needles using Debiotech's Micro Electromechanical
Systems (MEMS) microfluidic technology.
Nobex has partnered with Biocon of India to accelerate its project
to develop an oral formulation of insulin, to provide a more
patient-friendly alternative to current injectable products for
diabetes.
Pre-school youngsters with type I diabetes can be treated as
successfully with insulin pumps as with daily injections,
researchers at the Indiana University School of Medicine report.
Danish pharmaceutical company Novo Nordisk has decided to put its
weight behind the inhaled insulin project it has been pursuing
alongside US drug delivery specialist Aradigm.
A team of US researchers has developed a new microgel film that
could be used to create implants that release drugs into the body -
on demand - by applying small variations in heat.
Drug delivery company Nektar Therapeutics has bounced back from a
recent share slump after reporting encouraging new data supporting
the safety of its inhaled insulin product Exubera.
MannKind has presented new data on its inhaled insulin product that
suggest it may not only make dosing the drug more convenient, but
also improve efficacy compared to insulin injections.
The race to develop an inhaled formulation of insulin - and provide
the first alternative to injections for the millions of people
worldwide who suffer from diabetes - is getting closer.
Merck & Co continued a run of bad luck in its product
development portfolio yesterday with the news that it had
terminated the development of a drug to treat diabetes.
French company Flamel Technologies has added another high-profile
client for its drug delivery technology spurring another leap in
its shares that have already climbed almost 800 per cent over the
last 12 months.
Emisphere Technologies has demonstrated effective oral delivery of
protein-based drugs in three studies presented at the Controlled
Release Society's annual meeting.
Novo Nordisk has sent out the first batch of bulk insulin from a
new facility at its site in Kalundborg, Denmark, that is producing
more than a third of the world's supply.
There has been a steady increase in the number of diabetes-related
R&D projects in recent years, and one area of particular
interest is the pulmonary delivery of insulin, says a new report
